Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.80 |
| ▸ | ANPEP | P15144 | 2/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | XIAP | P98170 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | SCN4A | P35499 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL902633 | 1.00 | EPHX1 (0.80) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL902607 | 1.00 | EPHX1 (0.80) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL15476621 | 1.00 | EPHX1 (0.80) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL18034347 | 1.00 | EPHX1 (0.80) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| Hydrochloric Acid SCHEMBL16279669 | 0.97 | EPHX1 (0.76) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| Hydrochloric Acid SCHEMBL31169575 | 0.97 | EPHX1 (0.76) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| Hydrochloric Acid SCHEMBL16279671 | 0.97 | EPHX1 (0.76) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL16137191 | 0.93 | EPHX1 (0.70) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL20466361 | 0.90 | EPHX1 (0.73) | EPHX1ANPEPSLC6A2TAAR1MAOA | |
| SCHEMBL4303544 | 0.90 | EPHX1 (0.73) | EPHX1ANPEPSLC6A2TAAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115417829-A | Preparation method of ritonavir enantiomer | 武汉海特生物创新医药研究有限公司 | 2022-12-02 | — | — | CN | claimed |
| US-20140051888-A1 | NOVEL STEREOISOMERIC MIXTURES, SYNTHESIS AND USES THEREOF | AMPAC FINE CHEMICALS LLC (US) | 2014-02-20 | — | — | US | claimed |
| CN-109912426-B | Intermediate for synthesizing anti-AIDS medicine intensifier cobicistat | 上海奥博生物医药股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-109912426-B | Intermediate for synthesizing anti-AIDS medicine intensifier cobicistat | 上海奥博生物医药股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-115417829-A | Preparation method of ritonavir enantiomer | 武汉海特生物创新医药研究有限公司 | 2022-12-02 | — | — | CN | disclosed |
| EP-3696171-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3689353-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3112355-B1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES INC (US) | 2020-04-29 | — | — | EP | disclosed |
| CN-107417548-B | Cobicistat intermediate and preparation method thereof | 常州制药厂有限公司 | 2020-02-14 | — | — | CN | disclosed |
| US-10351556-B2 | Process for the preparation of 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2s)-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4YL] methyl} carbamoyl) amino]-4-(morpholin-4-yl)butanoyl]amino)-1,6-diphenylhexan-2-yl]carbamate | MSN LABORATORIES PRIVATE LIMITED (IN) | 2019-07-16 | — | — | US | disclosed |
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| EP-0997459-A1 | Intermediates for preparing retroviral protease inhibiting compounds | Abbott Laboratories (US) | 2000-05-03 | — | — | EP | disclosed |
| US-5837873-A | PROTECTED OXYDIAMINES | ABBOTT LABORATORIES (US) | 1998-11-17 | — | — | US | disclosed |
| US-5648497-A | Retroviral protease inhibiting compounds | ABBOTT LABORAOTRIES (US) | 1997-07-15 | — | — | US | disclosed |
| US-5616714-A | PYRIDYL, THIAZOLYL-SUBSTITUTED AMINO ACID DERIVATIVES | ABBOTT LABORATORIES (US) | 1997-04-01 | — | — | US | disclosed |
| US-5597926-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1997-01-28 | — | — | US | disclosed |
| US-5554783-A | (2R, 3R, 4S, 5S)-3-ACETOXY-2,5-BIS/BENZYLOXYCARBONYLAMINO/ -4-BROMO-1,5-DIPHENYLHEXANE | ABBOTT LABORATORIES (US) | 1996-09-10 | — | — | US | disclosed |
| US-5541334-A | TREATING HIV | ABBOTT LABORATORIES (US) | 1996-07-30 | — | — | US | disclosed |
| US-5354866-A | Treating HIV infections | ABBOTT LABORATORIES (US) | 1994-10-11 | — | — | US | disclosed |
| EP-0486948-A2 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1992-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051888-A1 | NOVEL STEREOISOMERIC MIXTURES, SYNTHESIS AND USES THEREOF | DDT, DPYD, DHPS | EPHX1 639/4885ANPEP 814/4885SLC6A2 2951/4885 |
| US-10351556-B2 | Process for the preparation of 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2s)-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4YL] methyl} carbamoyl) amino]-4-(morpholin-4-yl)butanoyl]amino)-1,6-diphenylhexan-2-yl]carbamate | METTL3, CPS1, PKD1 | EPHX1 4404/4885ANPEP 2151/4885SLC6A2 4799/4885 |
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | EPHX1 1708/4885ANPEP 550/4885SLC6A2 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.